Difficulty: Medium
Average Score: 86%
Practice
An 11-year-old boy has just arrived in the ER with cystic fibrosis and a pulmonary infection. Upon assessment, you note very thick secretions. Which of the following drugs would you recommend for this patient?
Correct answer
B
Rationale
In this scenario, the correct answer is B) Nebulized dornase alpha. Dornase alpha is a recombinant human deoxyribonuclease enzyme that helps to break down the thick DNA in the respiratory secretions of patients with cystic fibrosis. This drug specifically targets the underlying cause of the thick secretions in cystic fibrosis, which is the accumulation of thick mucus due to dysfunctional chloride channels.
Option A) Nebulized acetylcysteine is used to break down disulfide bonds in mucus but is not as effective in cystic fibrosis as dornase alpha. Option C) Nebulized 0.9% saline is used for hydration and humidification but does not target the root cause of the thick secretions in cystic fibrosis. Option D) Direct instillation of acetylcysteine into the lungs is not a common or recommended method of administration for this drug.
Educationally, understanding the rationale behind choosing the correct medication for a patient with cystic fibrosis and a pulmonary infection is crucial for healthcare providers. It highlights the importance of targeted therapies in managing specific conditions and underscores the need for evidence-based practice in selecting the most effective treatment options for individual patients.
Option A) Nebulized acetylcysteine is used to break down disulfide bonds in mucus but is not as effective in cystic fibrosis as dornase alpha. Option C) Nebulized 0.9% saline is used for hydration and humidification but does not target the root cause of the thick secretions in cystic fibrosis. Option D) Direct instillation of acetylcysteine into the lungs is not a common or recommended method of administration for this drug.
Educationally, understanding the rationale behind choosing the correct medication for a patient with cystic fibrosis and a pulmonary infection is crucial for healthcare providers. It highlights the importance of targeted therapies in managing specific conditions and underscores the need for evidence-based practice in selecting the most effective treatment options for individual patients.